Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.
Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...
The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).
Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients with ...
Can Diabetic Macular Edema (DME) Be Prevented? What to Know About Early Detection and Risk Reduction
DME is a diabetes complication that threatens your the clarity of your vision. But managing blood sugar, blood pressure, and ...
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...
Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –– Topline data for ...
A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...
The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
Fluocinolone implants can slow diabetic retinopathy and delay proliferation in patients with diabetic macular edema, researchers say. Compared with antivascular endothelial growth factor (anti-VEGF) ...
August 10, 2012 — The US Food and Drug Administration (FDA) has approved ranibizumab (Lucentis, Genentech) intravitreal injection for the treatment of diabetic macular edema (DME), according to an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results